Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
127,918 | 89,511 | 72,704 | 72,031 | 237,032 |
Cost of Goods Sold (COGS) incl. D&A |
7,510 | 5,832 | NA | NA | NA |
COGS excluding D&A |
832 | 496 | NA | NA | NA |
Depreciation & Amortization Expense |
6,678 | 5,336 | 1,218 | 1,274 | 1,068 |
Gross Income |
120,408 | 83,679 | NA | NA | NA |
SG&A Expense |
155,681 | 146,188 | 124,045 | 118,330 | 135,531 |
Research & Development |
82,572 | 85,667 | 76,356 | 80,660 | 83,989 |
Other SG&A |
73,109 | 60,521 | 47,689 | 37,670 | 51,542 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
3,083 | 9,951 | 53,174 | 3,527 | -120,403 |
Non Operating Income/Expense |
94 | -1,086 | 4,424 | -556 | 1,150 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
5,659 | 5,456 | 5,374 | 5,296 | 5,069 |
Gross Interest Expense |
5,659 | 5,456 | 5,374 | 5,296 | 5,069 |
Pretax Income |
-43,921 | -78,377 | -106,064 | -56,194 | 216,917 |
Income Tax |
-999 | -95,773 | -15 | 18 | 242 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
-42,922 | 17,396 | -106,049 | -56,212 | 216,675 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
-42,922 | 17,396 | -106,049 | -56,212 | 216,675 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
-42,922 | 17,396 | -106,049 | -56,212 | 216,675 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
-42,922 | 17,396 | -106,049 | -56,212 | 216,675 |
Operational EPS |
-0.63 | 0.36 | -1.07 | -0.84 | 2.07 |
EPS (basic) |
-0.64 | 0.26 | -1.65 | -0.88 | 3.42 |
EBITDA |
-28,595 | -57,173 | -52,559 | -8,629 | 101,501 |
Depreciation & Amortization Expense |
6,678 | 5,336 | 1,218 | 1,274 | 1,068 |
Common Shares Outstanding |
65,148 | 68,463 | 64,209 | 63,697 | 64,010 |
Basic Shares Outstanding |
65,148 | 65,831 | 64,209 | 63,697 | 63,422 |
Diluted Shares Outstanding |
65,148 | 68,463 | 64,209 | 63,697 | 64,010 |
Diluted EPS after Extraordinary Items |
-0.66 | 0.25 | -1.65 | -0.88 | 3.39 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
-0.66 | 0.26 | -1.65 | -0.88 | 3.39 |
*Figures in thousands of U.S. Dollars except shares outstanding.
